https://2meoe2inhibitor.com/re....lative-research-tons
Therefore, the recognition of novel representatives for particular TNBC targeting and treatment is desperately required. Here, by integrating cell-SELEX (Systematic advancement of Ligands by EXponential enrichment) when it comes to certain recognition of TNBC cells with high-throughput sequencing technology, we identified a panel of 2'-fluoropyrimidine-RNA aptamers binding to TNBC cells and their cisplatin- and doxorubicin-resistant types at reasonable nanomola
Like
Comment
Share
